International Survey of Gastroenterologists on Managing Inflammatory Bowel Disease During Pregnancy and Lactation: Current State and the Necessity for Improvements

Simple item page
dc.coverageDOI: 10.1002/ueg2.70122
dc.creatorCasanova, María José
dc.creatorGisbert, Javier P.
dc.creatorAmiot, Aurelien
dc.creatorGordon, Hannah
dc.creatorFiorino, Gionata
dc.creatorFlanagan, Emma
dc.creatorKotze, Paulo Gustavo
dc.creatorSokic-Milutinovic, Aleksandra
dc.creatorSonnenberg, Elena
dc.creatorNuñez, Paulina
dc.creatorBlesl, Andreas
dc.creatorCatalán-Serra, Ignacio
dc.creatorBossuyt, Peter
dc.creatorFilip, Rafal
dc.creatorBar-Gil Shitrit, Ariella
dc.creatorKagramanova, Anna
dc.creatorKrznaric, Zeljko
dc.creatorMolander, Paulina
dc.creatorMantzaris, Gerassimos J.
dc.creatorJuillerat, Pascal
dc.creatorMolnar, Tamas
dc.creatorGecse, Krisztina B.
dc.creatorTorres, Joana
dc.creatorMyrelid, Pär
dc.creatorMahadevan, Uma
dc.creatorMárquez, Juan Ricardo
dc.creatorIade-Vergara, Beatriz Maria
dc.creatorRausch, Astrid
dc.creatorDuricova, Dana
dc.creatorJulsgaard, Mette
dc.creatorChaparro, María
dc.date2025
dc.date.accessioned05-01-2026 18:18
dc.date.available05-01-2026 18:18
dc.description<p>Background: Reproduction is a fundamental aspect of life. This study aimed to provide an international overview of gastroenterologists' approaches to managing inflammatory bowel disease (IBD) during preconception, pregnancy, lactation, and postpartum. Methods: An anonymous 75-question survey was distributed to gastroenterologists in 36 countries, including European countries, the United States of America, Latin American countries, Australia, and New Zealand, focusing on clinical practices for managing pregnancy and breastfeeding in IBD patients. Results: A total of 856 gastroenterologists participated, 61% were IBD specialists. In pregnant patients in remission, participants stated they would discontinue IBD therapy as follows: 19% for thiopurines, 41% for anti-TNF, 37% for vedolizumab, 31% for ustekinumab, and 96% for small molecules. Many gastroenterologists avoided initiating oral or rectal budesonide, anti-TNF, vedolizumab, or ustekinumab during disease flares. Despite existing safety concerns, one-third of gastroenterologists reported initiating thiopurines to manage disease flares during pregnancy. Only 50% of gastroenterologists had specialized follow-up programs for pregnant patients with IBD in remission. Thirteen percent of gastroenterologists believed that all drugs were safe during breastfeeding. For vaccinations, about 20% advised against non-live vaccines, and 50% avoided live-vaccines during the first 12 months for infants exposed to anti-TNF in utero. Few gastroenterologists had referral pathways to IBD-specialized obstetricians or paediatricians. Conclusion: Our international survey suggests that management of IBD during pregnancy, lactation, and postpartum remains suboptimal, even among gastroenterologists specifically dedicated to IBD. Urgent educational efforts are needed to address these issues and improve care.</p>eng
dc.identifierhttps://investigadores.uandes.cl/en/publications/ef18fc07-f062-430b-922e-7cf2021b974a
dc.languageeng
dc.rightsinfo:eu-repo/semantics/openAccess
dc.sourcevol.13 (2025) nr.10 p.1999-2011
dc.subjectCrohn's disease
dc.subjectbiologics
dc.subjectinflammatory bowel disease
dc.subjectlactation
dc.subjectpregnancy
dc.subjectulcerative colitis
dc.subjectSDG 3 - Good Health and Well-being
dc.titleInternational Survey of Gastroenterologists on Managing Inflammatory Bowel Disease During Pregnancy and Lactation: Current State and the Necessity for Improvementseng
dc.typeArticleeng
dc.typeArtículospa
Files
Collections
Clínica UANDES